-
Something wrong with this record ?
Induction of fecal cholesterol excretion is not effective for the treatment of hyperbilirubinemia in Gunn rats
M. Blankestijn, IP. van de Peppel, A. Dvorak, N. Capkova, L. Vitek, JW. Jonker, HJ. Verkade
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1967 to 1 year ago
ProQuest Central
from 2016-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2016-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2021-01-01 to 2021-12-31
- MeSH
- Bilirubin chemistry MeSH
- Cholesterol metabolism MeSH
- Crigler-Najjar Syndrome metabolism therapy MeSH
- Dietary Fats pharmacokinetics MeSH
- Ezetimibe pharmacology therapeutic use MeSH
- Feces chemistry MeSH
- Hydrocarbons, Fluorinated pharmacology therapeutic use MeSH
- Haptoglobins analysis MeSH
- Hyperbilirubinemia therapy MeSH
- Liver X Receptors metabolism MeSH
- Rats MeSH
- Chenodeoxycholic Acid analogs & derivatives pharmacology therapeutic use MeSH
- Lipids blood MeSH
- Random Allocation MeSH
- Rats, Gunn MeSH
- PPAR delta metabolism MeSH
- Receptors, Cytoplasmic and Nuclear metabolism MeSH
- Intestines drug effects metabolism MeSH
- Sulfonamides pharmacology therapeutic use MeSH
- Bile chemistry MeSH
- Bile Acids and Salts metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Unconjugated hyperbilirubinemia, a feature of neonatal jaundice or Crigler-Najjar syndrome, can lead to neurotoxicity and even death. We previously demonstrated that unconjugated bilirubin (UCB) can be eliminated via transintestinal excretion in Gunn rats, a model of unconjugated hyperbilirubinemia, and that this is stimulated by enhancing fecal fatty acid excretion. Since transintestinal excretion also occurs for cholesterol (TICE), we hypothesized that increasing fecal cholesterol excretion and/or TICE could also enhance fecal UCB disposal and subsequently lower plasma UCB concentrations. METHODS: To determine whether increasing fecal cholesterol excretion could ameliorate unconjugated hyperbilirubinemia, we treated hyperbilirubinemic Gunn rats with ezetimibe (EZE), an intestinal cholesterol absorption inhibitor, and/or a liver X receptor (LXR) and farnesoid X receptor (FXR) agonist (T0901317 (T09) and obeticholic acid (OCA), respectively), known to stimulate TICE. RESULTS: We found that EZE treatment alone or in combination with T09 or OCA increased fecal cholesterol disposal but did not lower plasma UCB levels. CONCLUSIONS: These findings do not support a link between the regulation of transintestinal excretion of cholesterol and bilirubin. Furthermore, induction of fecal cholesterol excretion is not a potential therapy for unconjugated hyperbilirubinemia. IMPACT: Increasing fecal cholesterol excretion is not effective to treat unconjugated hyperbilirubinemia. This is the first time a potential relation between transintestinal excretion of cholesterol and unconjugated bilirubin is investigated. Transintestinal excretion of cholesterol and unconjugated bilirubin do not seem to be quantitatively linked. Unlike intestinal fatty acids, cholesterol cannot "capture" unconjugated bilirubin to increase its excretion. These results add to our understanding of ways to improve and factors regulating unconjugated bilirubin disposal in hyperbilirubinemic conditions.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012534
- 003
- CZ-PrNML
- 005
- 20220506130146.0
- 007
- ta
- 008
- 220425s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41390-020-0926-2 $2 doi
- 035 __
- $a (PubMed)32357361
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Blankestijn, Maaike $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
- 245 10
- $a Induction of fecal cholesterol excretion is not effective for the treatment of hyperbilirubinemia in Gunn rats / $c M. Blankestijn, IP. van de Peppel, A. Dvorak, N. Capkova, L. Vitek, JW. Jonker, HJ. Verkade
- 520 9_
- $a BACKGROUND: Unconjugated hyperbilirubinemia, a feature of neonatal jaundice or Crigler-Najjar syndrome, can lead to neurotoxicity and even death. We previously demonstrated that unconjugated bilirubin (UCB) can be eliminated via transintestinal excretion in Gunn rats, a model of unconjugated hyperbilirubinemia, and that this is stimulated by enhancing fecal fatty acid excretion. Since transintestinal excretion also occurs for cholesterol (TICE), we hypothesized that increasing fecal cholesterol excretion and/or TICE could also enhance fecal UCB disposal and subsequently lower plasma UCB concentrations. METHODS: To determine whether increasing fecal cholesterol excretion could ameliorate unconjugated hyperbilirubinemia, we treated hyperbilirubinemic Gunn rats with ezetimibe (EZE), an intestinal cholesterol absorption inhibitor, and/or a liver X receptor (LXR) and farnesoid X receptor (FXR) agonist (T0901317 (T09) and obeticholic acid (OCA), respectively), known to stimulate TICE. RESULTS: We found that EZE treatment alone or in combination with T09 or OCA increased fecal cholesterol disposal but did not lower plasma UCB levels. CONCLUSIONS: These findings do not support a link between the regulation of transintestinal excretion of cholesterol and bilirubin. Furthermore, induction of fecal cholesterol excretion is not a potential therapy for unconjugated hyperbilirubinemia. IMPACT: Increasing fecal cholesterol excretion is not effective to treat unconjugated hyperbilirubinemia. This is the first time a potential relation between transintestinal excretion of cholesterol and unconjugated bilirubin is investigated. Transintestinal excretion of cholesterol and unconjugated bilirubin do not seem to be quantitatively linked. Unlike intestinal fatty acids, cholesterol cannot "capture" unconjugated bilirubin to increase its excretion. These results add to our understanding of ways to improve and factors regulating unconjugated bilirubin disposal in hyperbilirubinemic conditions.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a žluč $x chemie $7 D001646
- 650 _2
- $a žlučové kyseliny a soli $x metabolismus $7 D001647
- 650 _2
- $a bilirubin $x chemie $7 D001663
- 650 _2
- $a kyselina chenodeoxycholová $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D002635
- 650 _2
- $a cholesterol $x metabolismus $7 D002784
- 650 _2
- $a Criglerův-Najjarův syndrom $x metabolismus $x terapie $7 D003414
- 650 _2
- $a dietní tuky $x farmakokinetika $7 D004041
- 650 _2
- $a ezetimib $x farmakologie $x terapeutické užití $7 D000069438
- 650 _2
- $a feces $x chemie $7 D005243
- 650 _2
- $a haptoglobiny $x analýza $7 D006242
- 650 _2
- $a fluorované uhlovodíky $x farmakologie $x terapeutické užití $7 D006845
- 650 _2
- $a hyperbilirubinemie $x terapie $7 D006932
- 650 _2
- $a střeva $x účinky léků $x metabolismus $7 D007422
- 650 _2
- $a lipidy $x krev $7 D008055
- 650 _2
- $a jaterní receptor X $x metabolismus $7 D000071518
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a PPAR delta $x metabolismus $7 D047494
- 650 _2
- $a náhodné rozdělení $7 D011897
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Gunn $7 D011911
- 650 _2
- $a receptory cytoplazmatické a nukleární $x metabolismus $7 D018160
- 650 _2
- $a sulfonamidy $x farmakologie $x terapeutické užití $7 D013449
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a van de Peppel, Ivo P $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
- 700 1_
- $a Dvorak, Ales $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and First Faculty of Medicine, Charles University, Na Bojisti 3, 12108, Prague, Czech Republic
- 700 1_
- $a Capkova, Nikola $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and First Faculty of Medicine, Charles University, Na Bojisti 3, 12108, Prague, Czech Republic
- 700 1_
- $a Vitek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and First Faculty of Medicine, Charles University, Na Bojisti 3, 12108, Prague, Czech Republic
- 700 1_
- $a Jonker, Johan W $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
- 700 1_
- $a Verkade, Henkjan J $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. h.j.verkade@umcg.nl
- 773 0_
- $w MED00003741 $t Pediatric research $x 1530-0447 $g Roč. 89, č. 3 (2021), s. 510-517
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32357361 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130138 $b ABA008
- 999 __
- $a ok $b bmc $g 1789933 $s 1163735
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 89 $c 3 $d 510-517 $e 20200501 $i 1530-0447 $m Pediatric research $n Pediatr Res $x MED00003741
- LZP __
- $a Pubmed-20220425